title: Monitoring response to gefitinib in nude mouse tumor xenografts by (18)F-FDG microPET-CT: correlation between (18)F-FDG uptake and pathological response.
abstract: BACKGROUND
  The purpose of this study is to investigate whether (18)F-fluorodeoxyglucose (FDG) micro-positron emission tomography-computed tomography (microPET-CT) can be used to monitor a metabolic response to gefitinib in nude mouse tumor xenografts.
  
  
  METHODS
  Sixteen nude mice were implanted with human A431 epidermoid carcinoma cells and ten with human A549 lung adenocarcinoma cells, and the tumors were allowed to grow to an approximate size of 150 mm(3). Ten and five of these mice, respectively, received intragastric gefitinib (100 mg/kg) once daily for 14 days, whereas six and five, respectively, received sterile water. Tumor metabolic activity was assessed by (18)F-FDG microPET imaging before treatment (day 0) and on days 2, 7, and 14. Tumor uptake of (18)F-FDG was determined from a region-of-interest drawn around the tumor, and the maximum percentage injected dose per gram (%ID/gmax) was calculated. Tumor volume measured on day 14 by microCT was used to categorize tumors as sensitive, stable, or resistant to gefitinib, and pathologic changes in these tumors were analyzed.
  
  
  RESULTS
  On day 2, the average changes in (18)F-FDG uptake by A431 tumors sensitive, stable, and resistant to gefitinib were -30.92% ± 6.66%, -5.68% ± 6.95%, and 7.72% ± 3.85%, respectively (P < 0.05 each), with no significant differences in the sizes of tumors sensitive and stable to gefitinib (P = 0.169). On day 7, sensitive tumors were significantly smaller than stable tumors (P = 0.034). On day 14, areas of necrosis were observed in gefitinib-sensitive tumors, with tumor necrosis ratios differing significantly among the sensitive, stable, and control groups (P < 0.05 each). In mice implanted with A549 cells, however, tumor (18)F-FDG uptake, volume, and percent necrosis did not differ significantly between gefitinib-treated and untreated mice on days 0, 2, 7, and 14 (P > 0.05 each).
  
  
  CONCLUSIONS
  F-FDG uptake is a sensitive method of detecting metabolic changes in tumors associated with therapy in vivo.
authors.affiliation: Department of Diagnostic Radiology, Cancer Hospital, Chinese Academy of Medical Sciences, No.17, Pan Jia Yuan Nan-li, Beijing, 100021, China. ts20001020@163.com.
authors.forename: Li-Na
authors.initials: LN
authors.lastname: Zhou
authors.affiliation: Department of Diagnostic Radiology, Cancer Hospital, Chinese Academy of Medical Sciences, No.17, Pan Jia Yuan Nan-li, Beijing, 100021, China. cjr.wuning@vip.163.com.|PET-CT Center, Cancer Hospital, Chinese Academy of Medical Sciences, No.17, Pan Jia Yuan Nan-li, Beijing, 100021, China. cjr.wuning@vip.163.com.
authors.forename: Ning
authors.initials: N
authors.lastname: Wu
authors.affiliation: PET-CT Center, Cancer Hospital, Chinese Academy of Medical Sciences, No.17, Pan Jia Yuan Nan-li, Beijing, 100021, China. liangy_2000@sina.com.
authors.forename: Ying
authors.initials: Y
authors.lastname: Liang
authors.affiliation: Key Laboratory of Human Disease Comparative Medicine, Ministry of Heath, Institute of Laboratory Animal Science, Peking Union Medical College, Chinese Academy of Medical Science, No.5, Pan Jia Yuan Nan-li, Beijing, 100021, China. gaokai1982@gmail.com.
authors.forename: Kai
authors.initials: K
authors.lastname: Gao
authors.affiliation: Key Laboratory of Human Disease Comparative Medicine, Ministry of Heath, Institute of Laboratory Animal Science, Peking Union Medical College, Chinese Academy of Medical Science, No.5, Pan Jia Yuan Nan-li, Beijing, 100021, China. lixiaoyinghebei@163.com.
authors.forename: Xiao-Ying
authors.initials: XY
authors.lastname: Li
authors.affiliation: Key Laboratory of Human Disease Comparative Medicine, Ministry of Heath, Institute of Laboratory Animal Science, Peking Union Medical College, Chinese Academy of Medical Science, No.5, Pan Jia Yuan Nan-li, Beijing, 100021, China. zhanglf@cnilas.org.
authors.forename: Lian-Feng
authors.initials: LF
authors.lastname: Zhang
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology*; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D049268:Positron-Emission Tomography / Q000379:methods*; D011799:Quinazolines / Q000627:therapeutic use*; D012372:ROC Curve; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D014018:Tissue Distribution; D014057:Tomography, X-Ray Computed / Q000379:methods*; D014407:Tumor Cells, Cultured; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D000077156:Gefitinib